DeutschNewstral
Article
Mmarketwatch.com on 2016-09-06 18:54
Sage Therapeutics stock rises 12% after FDA designates drug a 'breakthrough therapy'
Related news
FDA Approves Sage Therapeutics’ Zulressowsj.com
FDA approves Spark Therapeutics' gene therapy treatment; pricing questions remainbizjournals.com- United Therapeutics gets another FDA approval for pulmonary hypertension therapybizjournals.com
- FDA advisory panel recommends approval of Spark Therapeutics' gene therapybizjournals.com
Spark Therapeutics Gene Therapy for Blindness Moves Forward With FDAphillymag.com- MBeiGene drug gets 'breakthrough therapy' designation from FDAmarketwatch.com
Digital therapy program for fibromyalgia receives FDA breakthrough device designationTechCrunch- Breakthrough cancer therapy developed at Penn receives 2nd FDA approvalbizjournals.com
- MInjectable PrEP receives ‘breakthrough therapy’ designation from FDAmetroweekly.com
- DFDA calls ecstasy a 'breakthrough' drug for PTSD therapyDaily News
FDA Unveils Considerations for Rescinding Breakthrough Therapy Designationjdsupra.com
Celcuity secures FDA 'breakthrough therapy designation' for breast cancer drugStar Tribune- Sage Therapeutics asks FDA to approve lead drug for postpartum depressionbizjournals.com
Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDAnewatlas.com- FDA accepts for priority review Spark Therapeutics' gene therapy for blindnessbizjournals.com
- MMersana Therapeutics says FDA has lifted partial clinical hold on cancer therapy trialmarketwatch.com
- MSpark Therapeutics shares halted as FDA committee reviews gene therapy treatment for eye diseasemarketwatch.com
- MSpark Therapeutics shares rise on FDA approval of new gene therapy for blindnessmarketwatch.com
- MFlexion Therapeutics stock soars 24% premarket as FDA approves label change for OA keen pain therapymarketwatch.com